Uncategorized

U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has approved a new indication for PREVYMIS® for prophylaxis of cytomegalovirus disease in adult kidney transplant recipients at high risk following a priority review.

U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients Read More »

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the final closing of a private placement resulting in gross proceeds to Zura Bio of approximately $80 million.

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist Read More »

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

Ascentage Pharma announced that it has released preliminary results from a Phase Ib/II study of the Bcl-2 inhibitor, lisaftoclax, as a monotherapy or combined with ibrutinib or rituximab in patients with Waldenström macroglobulinemia, in a Poster Presentation at the 59th American Society of Clinical Oncology Annual Meeting that marked the first data readout from a

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential Read More »

Scroll to Top